keyword
MENU ▼
Read by QxMD icon Read
search

ziv-aflibercept

keyword
https://www.readbyqxmd.com/read/28712102/precision-medicine-in-metastatic-colorectal-cancer-relevant-carcinogenic-pathways-and-targets-part-2-approaches-beyond-first-line-therapy-and-novel-biologic-agents-under-investigation
#1
REVIEW
Benjamin A Weinberg, Marion L Hartley, Mohamed E Salem
A frequent quandary for oncologists is the selection of chemotherapy and biologic therapy for patients with metastatic colorectal cancer in second-line and higher treatment settings. While not approved by the US Food and Drug Administration (FDA) in the first-line setting, the vascular endothelial growth factor (VEGF)-targeting agents ziv-aflibercept and ramucirumab are appropriate treatment options in the second-line setting, as is continuation of first-line bevacizumab. Tumor RAS mutational status is helpful to determine which patients may benefit from epidermal growth factor receptor (EGFR)-directed therapies, and other novel biomarkers (BRAF, HER2, and mismatch repair deficiency) allow us to select patients who may benefit from biologic therapies that are FDA-approved for other malignancies...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28712098/precision-medicine-in-metastatic-colorectal-cancer-relevant-carcinogenic-pathways-and-targets-part-1-biologic-therapies-targeting-the-epidermal-growth-factor-receptor-and-vascular-endothelial-growth-factor
#2
REVIEW
Benjamin A Weinberg, Marion L Hartley, Mohamed E Salem
The survival of patients with metastatic colorectal cancer has improved dramatically in recent years, with overall survival exceeding 3 years in large randomized clinical trials. There are now several treatment options for patients with metastatic colorectal cancer. In addition to chemotherapy backbones utilizing fluoropyrimidine, oxaliplatin, and irinotecan combinations, biologic agents that target specific oncogenic pathways have contributed to the improved survival observed in this patient population. This class of medications includes epidermal growth factor receptor (EGFR)-targeted drugs (cetuximab and panitumumab) and vascular endothelial growth factor (VEGF)-targeted therapies (bevacizumab, ramucirumab, ziv-aflibercept, and regorafenib)...
July 15, 2017: Oncology (Williston Park, NY)
https://www.readbyqxmd.com/read/28652928/ph-of-anti-vegf-agents-in-the-human-vitreous-low-impact-of-very-different-formulations
#3
Bianka Sobolewska, Peter Heiduschka, Karl-Ulrich Bartz-Schmidt, Focke Ziemssen
BACKGROUND: The aim of the study was to measure pH changes of the human vitreous caused by the intravitreal drugs bevacizumab, ranibizumab, aflibercept, and ziv-aflibercept. METHODS: Fresh human vitreous samples were obtained during core vitrectomy (23-gauge) from patients with epiretinal gliosis. Aliquots of bevacizumab, ranibizumab, aflibercept or ziv-aflibercept (2 µl) were added consecutively to 200 µl of vitreous samples or 0.9% NaCl saline. The pH was measured using a pH-sensitive microelectrode...
2017: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/28614154/regression-of-inflamed-pterygia-by-frequent-high-dose-intralesional-ziv-aflibercept
#4
Ahmad M Mansour
PURPOSE: Intralesional single low-dose vascular endothelial growth factor antagonists have traditionally failed in causing regression of pterygia. The current pilot study investigates the role of high-dose repeated intralesional ziv-aflibercept in causing regression of inflamed or recurring pterygia. METHODS: This prospective study from January 2015 to April 2017 consisted of using high dose of ziv-aflibercept between 0.1 mL (2.5 mg) and 0.3 mL (7.5 mg), depending on the pterygium size and the degree of inflammation...
June 13, 2017: Cornea
https://www.readbyqxmd.com/read/28596286/one-year-outcome-of-intravitreal-ziv-aflibercept-therapy-for-non-responsive-neovascular-age-related-macular-degeneration
#5
Imoro Zeba Braimah, Komal Agarwal, Ahmad Mansour, Jay Chhablani
AIM: To evaluate 12-month outcome of intravitreal ziv-aflibercept (IVZ) therapy in eyes with neovascular age-related macular degeneration (nAMD) that are non-responsive to bevacizumab and ranibizumab. METHODS: This retrospective study included 16 eyes (14 patients) with nAMD who were on prior treatment with bevacizumab and ranibizumab and were treated with as-needed IVZ (1.25 mg/0.05 mL) for 12 months. The primary outcome measure was the mean change in best corrected visual acuity (BCVA) and secondary outcome measures included mean change in central macular thickness (CMT), retinal pigment epithelial detachment (RPED) heights, longest treatment free interval, presence of subretinal fluid (SRF) and intraretinal fluid (IRF) and adverse events...
June 8, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28548650/aflibercept-in-age-related-macular-degeneration-evaluating-its-role-as-a-primary-therapeutic-option
#6
REVIEW
M Ashraf, A A R Souka
The recent VIEW studies have demonstrated the non-inferiority of monthly and bi-monthly aflibercept in the management of wet age related macular degeneration (AMD) compared with ranibizumab. However, the current data are limited mainly to fixed dosing regimens with few studies looking at flexible dosing regimens of aflibercept in wet AMD. In addition, recent data from the VIEW 96 week extension has shown that patients being shifted from fixed dosing regimens to PRN have shown a drop in visual acuity and increase in central macular thickness...
May 26, 2017: Eye
https://www.readbyqxmd.com/read/28499051/safety-and-efficacy-of-ziv-aflibercept-in-the-treatment-of-refractory-diabetic-macular-edema
#7
Mohammed Ashraf, Hassan El Kayal, Ahmed A R Souka
BACKGROUND AND OBJECTIVE: To evaluate the safety and efficacy of ziv-aflibercept (Zaltrap; Sanofi-Aventis, Bridgewater, NJ/Regeneron Pharmaceuticals, Tarrytown, NY) in the treatment of refractory diabetic macular edema (DME). PATIENTS AND METHODS: Retrospective case series looking at the safety of ziv-aflibercept in patients with DME refractory to previous anti-vascular endothelial growth factor (VEGF) therapy. Detailed ophthalmologic examination, best-corrected visual acuity, and optical coherence tomography measurements were performed pre-switch, as well as at each monthly follow-up visit...
May 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28280634/erratum-to-osteonecrosis-of-the-jaw-associated-with-ziv-aflibercept
#8
(no author information available yet)
[This corrects the article on p. E81 in vol. 7, PMID: 28078129.].
February 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28270485/long-term-safety-and-efficacy-of-ziv-aflibercept-in-retinal-diseases
#9
Ahmad M Mansour, Mohammed Ashraf, Chintan J Dedhia, Abdulrazzak Charbaji, Ahmed A R Souka, Jay Chhablani
AIMS: To investigate the long-term safety of intravitreal ziv-aflibercept in eyes receiving six or more intravitreal injections of ziv-aflibercept, an off-label substitute to the approved aflibercept. METHODS: Consecutive patients with retinal disease receiving six or more of intravitreal 0.05 mL ziv-aflibercept (1.25 mg) injections were followed monthly in three centres. Outcome measures were best-corrected visual acuity (BCVA) (logarithm of the minimum angle of resolution (logMar)) and central macular thickness (CMT) on spectral domain optical coherence tomography and monitoring for ocular inflammation, progression of lens opacities and intraocular pressure rise...
March 7, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28138259/advances-in-antiangiogenic-treatment-of-small-cell-lung-cancer
#10
REVIEW
Hongyang Lu, Zhiming Jiang
Small-cell lung cancer (SCLC), a poorly differentiated neuroendocrine malignancy, has a rapid growth rate, strong aggressiveness, early metastases, and poor prognosis. Angiogenesis greatly contributes to the metastatic process of SCLC, which has a higher vascularization compared with non-small-cell lung cancer (NSCLC). SCLC might constitute an ideal malignancy for assessing new antiangiogenic drugs and therapeutic strategies. Combining bevacizumab with paclitaxel has therapeutic benefits in chemoresistant, relapsed SCLC...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28119292/intravitreal-ziv-aflibercept-for-the-treatment-of-choroidal-neovascularisation-associated-with-conditions-other-than-age-related-macular-degeneration
#11
Imoro Zeba Braimah, Michael Stewart, Chetan Videkar, Chintan J Dedhia, Jay Chhablani
AIM: To report the short-term outcomes of eyes with choroidal neovascularisation (CNV) associated with causes other than age-related macular degeneration (AMD) after treatment with intravitreal ziv-aflibercept (IVZ) injections. METHODS: This retrospective study included eyes with non-AMD-related CNV that were treated with IVZ (1.25 mg/0.05 mL) on a pro re nata basis. The primary outcome measure is the mean change in best-corrected visual acuity (BCVA) and secondary outcome measures include the mean change in central macular thickness (CMT) and adverse events...
January 24, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28078129/osteonecrosis-of-the-jaw-associated-with-ziv-aflibercept
#12
Hani Mawardi, Peter Enzinger, Nadine McCleary, Reshma Manon, Alessandro Villa, Nathaniel Treister, Sook-Bin Woo
Medication-related osteonecrosis of the jaw (MRONJ) has been associated with medications that include bisphosphonates (BPs), denosumab, bevacizumab and sunitinib. Ziv-aflibercept is a recombinant human vascular endothelial growth factor (VEGF) receptor which has been used to treat patients with various advanced solid tumors. We report three patients without a history of the use of medications known to cause MRONJ presenting with jaw osteonecrosis typical for MRONJ following therapy with ziv-aflibercept. All patients had metastatic gastrointestinal cancer treated with ziv-aflibercept and were evaluated for MRONJ because of exposed bone in the oral cavity...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28060148/short-term-safety-of-2-mg-intravitreal-ziv-aflibercept
#13
Jay Chhablani, Chintan Jethalal Dedhia, Hari K Peguda, Michael Stewart
PURPOSE: To evaluate the safety of single intravitreal 2 mg ziv-aflibercept (0.08 mL) injections for the treatment of choroidal neovascular membranes (CNVM). METHODS: Eyes with choroidal neovascular membranes because of several conditions each received single intravitreal injections of 2 mg ziv-aflibercept (0.08 mL). Comprehensive ophthalmic examinations and detailed systemic evaluations were performed at baseline and Days 1, 7, and 30 after injections. Standard electroretinography was performed at baseline and Day 30...
January 2, 2017: Retina
https://www.readbyqxmd.com/read/27997919/viability-of-primary-human-pigment-epithelium-cells-and-muller-glia-cells-after-intravitreal-ziv-aflibercept-and-aflibercept
#14
Gabriel Costa de Andrade, Christian Wertheimer, Kirsten Eibl, Armin Wolf, Anselm Kampik, Eduardo Buchele Rodrigues, Michel Eid Farah, Christos Haritoglou
PURPOSE: The aim of this study was to access the safety profiles of 2 fusion proteins with anti-vascular endothelial growth factor action (ziv-aflibercept and aflibercept) on retinal pigment epithelium cells and Muller-Glia cells in culture by assessing cell viability post drug exposure. METHODS: Primary human retinal pigment epithelium cells (pRPE) and Muller-Glia cells (Mio-M1) were exposed to the clinical standardized concentrations of ziv-aflibercept (25 mg/mL) and aflibercept (40 mg/mL)...
2016: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/27888621/intraperitoneal-ziv-aflibercept-effectively-manages-refractory-ascites-in-colorectal-cancer-patients
#15
Chieh-Sheng Lu, Jen-Kou Lin, Wei-Shone Chen, Tzu-Chen Lin, Jeng-Kai Jiang, Shung-Haur Yang, Huann-Sheng Wang, Shih-Ching Chang, Yuan-Tzu Lan, Chun-Chi Lin, Hung-Hsin Lin, Hao-Wei Teng
Ascites related to metastatic colorectal cancer (mCRC) reduces patient survival and quality of life, and systemic chemotherapy is largely ineffective for managing ascites. Here, we examined the clinical efficacy of intraperitoneal (IP) ziv-aflibercept for managing refractory ascites in 15 mCRC patients who did not respond to standard chemotherapy. Fifty or 100 mg of ziv-aflibercept in 100 mL of saline solution were infused through a pigtail catheter and retained for 24 h. When the ascites drainage volumes were subsequently monitored, 73...
May 30, 2017: Oncotarget
https://www.readbyqxmd.com/read/27847621/fusion-proteins-for-treatment-of-retinal-diseases-aflibercept-ziv-aflibercept-and-conbercept
#16
REVIEW
João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Eduardo Amorim Novais, Michel Eid Farah, Eduardo Büchele Rodrigues
In the last few years, monoclonal antibodies have revolutionized the treatment of retinal neovascular diseases. More recently, a different class of drugs, fusion proteins, has provided an alternative treatment strategy with pharmacological differences. In addition to commercially available aflibercept, two other drugs, ziv-aflibercept and conbercept, have been studied in antiangiogenic treatment of ocular diseases. In this scenario, a critical review of the currently available data regarding fusion proteins in ophthalmic diseases may be a timely and important contribution...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27798520/clinical-and-electrophysiological-evaluation-after-intravitreal-ziv-aflibercept-for-exudative-age-related-macular-degeneration
#17
João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Vinicius Ferreira Kniggendorf, Eduardo Amorim Novais, André Maia, Carsten Meyer, Sung Eun Song Watanabe, Michel Eid Farah, Eduardo Büchele Rodrigues
PURPOSE: To evaluate the 6-month safety and efficacy of ziv-aflibercept intravitreal injections for treating exudative age-related macular degeneration. METHODS: Fifteen patients with unilateral exudative age-related macular degeneration were enrolled. The best-corrected visual acuity was measured and spectral domain optical coherence tomography was performed at baseline and monthly. Full-field electroretinography and multifocal electroretinography were obtained at baseline and 4, 13, and 26 weeks after the first injection...
August 2017: Retina
https://www.readbyqxmd.com/read/27703326/intravitreal-ziv-aflibercept-for-macular-edema-following-retinal-vein-occlusion
#18
Remya Paulose, Jay Chhablani, Chintan J Dedhia, Michael W Stewart, Ahmad M Mansour
AIM: To report the efficacy of intravitreal ziv-aflibercept injections in eyes with macular edema due to retinal vein occlusions (RVOs). METHODS: Consecutive patients with persistent or recurrent macular edema (central macula thickness >250 μm) due to RVO were enrolled in this prospective study. Study eyes received intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL) at baseline. Patients were reassessed monthly for 4 months and given additional injections pro re nata for worsening best-corrected visual acuity (BCVA), intraretinal edema or subretinal fluid seen on spectral domain optical coherence tomography, or central macular thickness (CMT) measurements >250 μm...
2016: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27435924/antiangiogenic-and-antitumor-activities-of-aflibercept-a-soluble-vegf-receptor-1-and-2-in-a-mouse-model-of-hepatocellular-carcinoma
#19
Takuji Torimura, Hideki Iwamoto, Toru Nakamura, Mitsuhiko Abe, Yu Ikezono, Fumitaka Wada, Takahiko Sakaue, Hiroshi Masuda, Osamu Hashimoto, Hironori Koga, Takato Ueno, Hirohisa Yano
BACKGROUND & AIM: Aflibercept known as ziv-aflibercept in the United States is a soluble decoy receptor of both vascular endothelial growth factor (VEGF) receptor-1 and -2 known to inhibit the binding of VEGF and placental growth factor (PlGF) to VEGF receptor-1 and -2. Here, we analyzed the mechanisms of the antitumor effects of aflibercept in mouse hepatoma models. METHODS: In in vitro studies, we determined the effects of aflibercept on human umbilical vein cell (HUVEC) proliferation and bone marrow (BM) cell differentiation to endothelial progenitor cells (EPCs)...
July 2016: Neoplasia: An International Journal for Oncology Research
https://www.readbyqxmd.com/read/27347566/three-month-outcome-of-ziv-aflibercept-for-diabetic-macular-edema
#20
Ameen Marashi
PURPOSE: Is to show the 3-month efficacy and safety of treatment diabetic macular edema treated with intravitreal ziv-aflibercept as studies have shown that Ziv-aflibercept does not cause retinal pigment epithelial toxicity and to study it cost effectiveness. METHODS: Ten eyes in eight patients diagnosed with central diabetic macular edema were enrolled for three consecutive intravitreal injection of ziv-aflibercept 1.25 mg every 4 weeks, a complete exam including BCVA and CRT at baseline and 12 weeks with evaluation of ocular and systemic complications...
2016: Advances in Ophthalmology & Visual System
keyword
keyword
66937
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"